PE20081362A1 - DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K - Google Patents

DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K

Info

Publication number
PE20081362A1
PE20081362A1 PE2007001151A PE2007001151A PE20081362A1 PE 20081362 A1 PE20081362 A1 PE 20081362A1 PE 2007001151 A PE2007001151 A PE 2007001151A PE 2007001151 A PE2007001151 A PE 2007001151A PE 20081362 A1 PE20081362 A1 PE 20081362A1
Authority
PE
Peru
Prior art keywords
inhibitors
phenyl
alkyl
mtor kinase
pi3k
Prior art date
Application number
PE2007001151A
Other languages
English (en)
Inventor
Maurice Raymond Verschoyle Finlay
Kurt Gordon Pike
Jeffrey Morris
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38720451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081362(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0616747A external-priority patent/GB0616747D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20081362A1 publication Critical patent/PE20081362A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE MORFOLINA PIRIMIDINA DE FORMULA (I), EN DONDE m ES DE 0 A 4; Y1 E Y2 SON INDEPENDIENTEMENTE N O CR8, CON LA CONDICION DE QUE UNO SEA N Y EL OTRO CR8; X ES UN LIGADOR SELECCIONADO ENTRE -CR4=CR5-, -NR4CR6R7-, -OCR6R7-, -SCR6R7-, -S(O)CR6R7-, ENTRE OTROS; R1 ES H, ALQUILO(C1-C6), ALQUENILO(C2-C6), CARBOCICLILO, ENTRE OTROS; R2 ES ALQUILO(C1-C6), CARBOCICLILO Y HETEROCICLILO SUSTITUIDO CON NR17CONR18R19, ENTRE OTROS; CADA R3 ES HALO, CIANO, NITRO, -R13, -OR13, SR13, SOR13, CO2R13, ENTRE OTROS; O R1 Y R4 JUNTOS CON EL ATOMO AL CUAL ESTAN UNIDOS FORMAN UN CARBOCICLILO O HETEROCICLILO. SON SELECCIONADOS: 1-ETIL-3-[4-[4-[(3S)-3-METILMORFOLIN-4-IL]-6-(METILSULFONILMETIL)PIRIMIDIN-2-IL)FENIL]UREA, 1-[4-[4-(METILSULFONILMETIL)-6-MORFOLIN-4-IL-PIRIMIDIN-2-IL]FENIL]-3-FENIL-UREA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. ESTOS COMPUESTOS SON INHIBIDORES DE LA mTOR QUINASA Y/O UNA O MAS ENZIMAS PI3K (TAL COMO LAS DE CLASE Ia Y/O Ib) POR LO QUE SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES PROLIFERATIVAS TAL COMO EL CANCER
PE2007001151A 2006-08-24 2007-08-24 DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K PE20081362A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0616747A GB0616747D0 (en) 2006-08-24 2006-08-24 Novel compounds
US94854407P 2007-07-09 2007-07-09

Publications (1)

Publication Number Publication Date
PE20081362A1 true PE20081362A1 (es) 2008-11-14

Family

ID=38720451

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001151A PE20081362A1 (es) 2006-08-24 2007-08-24 DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K

Country Status (16)

Country Link
US (1) US7750003B2 (es)
EP (1) EP2057140B1 (es)
JP (1) JP5534811B2 (es)
KR (1) KR101435231B1 (es)
AR (1) AR062526A1 (es)
AU (1) AU2007287428B2 (es)
CA (1) CA2660758A1 (es)
CL (1) CL2007002446A1 (es)
CO (1) CO6150160A2 (es)
HK (1) HK1130776A1 (es)
IL (1) IL196998A0 (es)
MX (1) MX2009002046A (es)
NO (1) NO20090631L (es)
PE (1) PE20081362A1 (es)
UY (1) UY30559A1 (es)
WO (1) WO2008023159A1 (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE448532T1 (de) * 1996-09-04 2009-11-15 Intertrust Tech Corp Zuverlässige infrastrukturhilfssysteme, verfahren und techniken für sicheren elektronischen handel, elektronische transaktionen, handelsablaufsteuerung und automatisierung, verteilte verarbeitung und rechteverwaltung
US7935715B2 (en) 2006-07-28 2011-05-03 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
CA2660758A1 (en) 2006-08-24 2008-02-27 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
JP5030114B2 (ja) 2006-09-25 2012-09-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体をモジュレートする化合物
EP2118069B1 (en) * 2007-01-09 2014-01-01 Amgen Inc. Bis-aryl amide derivatives useful for the treatment of cancer
CN101711241A (zh) * 2007-02-06 2010-05-19 诺瓦提斯公司 Pi3-激酶抑制剂和它们的使用方法
AU2008273889B2 (en) * 2007-07-09 2012-03-08 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
ATE554075T1 (de) * 2007-07-09 2012-05-15 Astrazeneca Ab Bei mit mtor-kinase und/oder pi3k in zusammenhang stehenden krankheiten angewendete morpholinopyrimidinderivate
US8546563B2 (en) 2007-11-07 2013-10-01 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
WO2009094224A1 (en) 2008-01-25 2009-07-30 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
ES2557281T3 (es) 2008-02-29 2016-01-25 Evotec Ag Compuestos amida, composiciones y usos de los mismos
WO2009140089A2 (en) * 2008-05-13 2009-11-19 Boehringer Ingelheim International Gmbh Sulfone compounds which modulate the cb2 receptor
CN102036995B (zh) 2008-05-23 2014-09-17 惠氏有限责任公司 作为PI3激酶和mTOR抑制剂的三嗪化合物
GEP20125650B (en) 2008-06-19 2012-09-25 Millennium Pharm Inc Thiophene or thiazole derivatives and use thereof as pi3k inhibitors
CA2730037A1 (en) 2008-07-10 2010-01-14 Boehringer Ingelheim International Gmbh Sulfone compounds which modulate the cb2 receptor
ES2432821T3 (es) * 2008-07-31 2013-12-05 Genentech, Inc. Compuestos de pirimidina, composiciones y métodos de utilización
WO2010030027A1 (en) 2008-09-10 2010-03-18 Mitsubishi Tanabe Pharma Corporation Aromatic nitrogen-containing 6-membered ring compounds and their use
US20110237578A1 (en) * 2008-09-18 2011-09-29 Zhi-Liang Wei Amide compounds, compositions and uses thereof
BRPI0919172A2 (pt) 2008-09-25 2015-12-15 Boehringer Ingelheim Int compostos os quais modulam seletivamente o receptor de cb2
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
UY32351A (es) 2008-12-22 2010-07-30 Astrazeneca Ab Compuestos de pirimidinil indol para uso como inhibidores de atr
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
CA2750935A1 (en) 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2010103094A1 (en) 2009-03-13 2010-09-16 Cellzome Limited PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2010120996A1 (en) * 2009-04-17 2010-10-21 Wyeth Llc 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
EP2419432B9 (en) * 2009-04-17 2016-02-17 Wyeth LLC Pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
WO2010120991A1 (en) * 2009-04-17 2010-10-21 Wyeth Llc 5, 6, 7, 8-tetrahydropyrido[4,3-d]pyrimidine compounds, their use as mtor, pi3, and hsmg-1 kinase inhibitors, and their syntheses
US20120071475A1 (en) * 2009-04-27 2012-03-22 Shionogi & Co., Ltd. Urea derivatives having pi3k-inhibiting activity
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
EP2443107B1 (en) 2009-06-16 2018-08-08 Boehringer Ingelheim International GmbH Azetidine 2 -carboxamide derivatives which modulate the cb2 receptor
EP3141252B8 (en) * 2009-06-17 2019-03-13 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
US20100331305A1 (en) * 2009-06-24 2010-12-30 Genentech, Inc. Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use
WO2011037795A1 (en) 2009-09-22 2011-03-31 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the cb2 receptor
AU2010313152A1 (en) 2009-10-30 2012-04-19 Ariad Pharmaceuticals, Inc. Methods and compositions for treating cancer
US8288381B2 (en) 2009-11-12 2012-10-16 Genentech, Inc. N-9 substituted purine compounds, compositions and methods of use
CA2780018C (en) 2009-11-12 2015-10-20 F. Hoffmann-La Roche Ag N-7 substituted purine and pyrazolopyrimidine compounds, compositions and methods of use
US9315491B2 (en) 2009-12-28 2016-04-19 Development Center For Biotechnology Pyrimidine compounds as mTOR and PI3K inhibitors
EP2523936A1 (en) 2010-01-15 2012-11-21 Boehringer Ingelheim International GmbH Compounds which modulate the cb2 receptor
EP2542536B1 (en) 2010-03-04 2015-01-21 Cellzome Limited Morpholino substituted urea derivatives as mtor inhibitors
WO2011109324A1 (en) 2010-03-05 2011-09-09 Boehringer Ingelheim International Gmbh Tetrazole compounds which selectively modulate the cb2 receptor
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
JP5746764B2 (ja) 2010-07-22 2015-07-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節する化合物
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
EP2603216A4 (en) 2010-08-11 2013-12-18 Millennium Pharm Inc HETEROARYLE AND USES THEREOF
KR20130098334A (ko) 2010-08-11 2013-09-04 밀레니엄 파머슈티컬스 인코퍼레이티드 헤테로아릴 및 이의 용도
CA2813333C (en) 2010-10-01 2019-01-15 Novartis Ag Manufacturing process for pyrimidine derivatives
TW201307309A (zh) 2010-10-13 2013-02-16 Millennium Pharm Inc 雜芳基化合物及其用途
WO2012058671A1 (en) 2010-10-31 2012-05-03 Endo Pharmaceuticals Inc. Substituted quinazoline and pyrido-pyrimidine derivatives
JP2014510122A (ja) 2011-04-04 2014-04-24 セルゾーム リミテッド ｍＴＯＲ阻害剤としてのジヒドロピロロピリミジン誘導体
CN102887867B (zh) * 2011-07-21 2015-04-15 中国科学院上海药物研究所 一类三嗪类化合物、该化合物的制备方法及其用途
JP2014521616A (ja) * 2011-07-26 2014-08-28 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング バニロイド受容体リガンドとしての置換ヘテロ芳香族ピラゾール含有カルボキサミドおよび尿素誘導体
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
ME02873B (me) * 2011-09-02 2018-04-20 Purdue Pharma Lp Pirimidini kao blokatori natrijumskog kanala
CN103917530B (zh) 2011-09-21 2016-08-24 塞尔佐姆有限公司 作为mtor抑制剂的吗啉代取代的脲或氨基甲酸衍生物
CN103946222B (zh) 2011-10-07 2016-12-28 塞尔佐姆有限公司 作为mtor抑制剂的吗啉代取代的双环嘧啶脲或氨基甲酸衍生物
EP2852661A1 (en) 2012-05-23 2015-04-01 F. Hoffmann-La Roche AG Compositions and methods of obtaining and using endoderm and hepatocyte cells
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
US9296727B2 (en) 2013-10-07 2016-03-29 Vertex Pharmaceuticals Incorporated Methods of regioselective synthesis of 2,4-disubstituted pyrimidines
KR102338461B1 (ko) 2013-11-13 2021-12-13 버텍스 파마슈티칼스 인코포레이티드 인플루엔자 바이러스 복제 억제제의 제조 방법
EP3578554A1 (en) 2013-11-13 2019-12-11 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
RU2748652C2 (ru) * 2014-05-21 2021-05-28 Аллерган, Инк. Производные имидазола как модуляторы формилпептидного рецептора
PE20170682A1 (es) 2014-08-04 2017-06-15 Nuevolution As Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados utiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncologicas y autoinmunitarias
WO2016183116A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
EP3294735B8 (en) 2015-05-13 2022-01-05 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2018218197A2 (en) 2017-05-26 2018-11-29 Board Of Regents, The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase
LT3651768T (lt) 2017-07-13 2024-04-25 Board Of Regents, The University Of Texas System Heterocikliniai atr kinazės inhibitoriai
US10800774B2 (en) 2017-08-17 2020-10-13 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of ATR kinase
CN112218631B (zh) 2018-03-16 2023-12-22 德州大学系统董事会 Atr激酶的杂环抑制剂
EP4076657A1 (en) 2019-12-20 2022-10-26 Nuevolution A/S Compounds active towards nuclear receptors
US11780843B2 (en) 2020-03-31 2023-10-10 Nuevolution A/S Compounds active towards nuclear receptors
US11613532B2 (en) 2020-03-31 2023-03-28 Nuevolution A/S Compounds active towards nuclear receptors

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3922735A1 (de) 1989-07-11 1991-01-24 Hoechst Ag Aminopyrimidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide
DE60144322D1 (de) * 2000-04-27 2011-05-12 Astellas Pharma Inc Kondensierte heteroarylderivate
JP3810017B2 (ja) * 2000-04-27 2006-08-16 アステラス製薬株式会社 縮合ヘテロアリール誘導体
ATE340784T1 (de) * 2000-11-10 2006-10-15 Hoffmann La Roche Pyrimidinderivate und deren verwendung als neuropeptid-y-rezeptorliganden
ATE527250T1 (de) * 2002-11-21 2011-10-15 Novartis Ag 2,4,6-trisubstituierten pyrimidinen als phosphotidylinositol (pi) 3-kinase inhibitoren und deren verwendung zur behandlung von krebs
EP1626725A4 (en) 2003-05-29 2006-06-14 Synta Pharmaceuticals Corp Heterocyclic compounds for the prevention and treatment of disorders associated with excessive bone formation
GB0415364D0 (en) * 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415365D0 (en) * 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415367D0 (en) * 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
WO2007084413A2 (en) 2004-07-14 2007-07-26 Ptc Therapeutics, Inc. Methods for treating hepatitis c
JP2008519850A (ja) * 2004-11-10 2008-06-12 シンタ ファーマシューティカルズ コーポレーション Ｉｌ−１２調節化合物
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
TW200720256A (en) * 2005-05-13 2007-06-01 Synta Pharmaceuticals Corp IL-12 modulatory compounds
CA2608726C (en) 2005-05-20 2013-07-09 Methylgene Inc. Inhibitors of vegf receptor and hgf receptor signaling
DE102005024494A1 (de) * 2005-05-27 2006-11-30 Bayer Healthcare Ag Verwendung von Cyanopyrimidinen
WO2007005673A1 (en) 2005-07-01 2007-01-11 Irm Llc Pyrimidine-substituted benzimidazole derivatives as protein kinase inhibitors
EP1911753A1 (en) 2005-07-29 2008-04-16 Takeda Pharmaceutical Company Limited Spiro-cyclic compound
BRPI0615781A2 (pt) 2005-09-01 2009-06-16 Array Biopharma Inc compostos inibidores de raf e métodos de uso destes
JP2007091649A (ja) 2005-09-29 2007-04-12 Taisho Pharmaceut Co Ltd ピリミジン誘導体及びその使用に関連する治療方法
JP4531027B2 (ja) 2005-09-29 2010-08-25 田辺三菱製薬株式会社 医薬組成物
WO2007041358A2 (en) 2005-09-30 2007-04-12 Miikana Therapeutics, Inc. Substituted pyrazole compounds
ES2401192T3 (es) 2005-09-30 2013-04-17 Vertex Pharmceuticals Incorporated Deazapurinas útiles como inhibidores de janus cinasas
GB2431156A (en) 2005-10-11 2007-04-18 Piramed Ltd 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
GB0520657D0 (en) * 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
DK1945631T3 (da) 2005-10-28 2012-10-22 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidinderivater til anvendelse som tyrosinkinaseinhibitorer til behandling af cancer
EP1970375A4 (en) 2005-11-29 2010-06-02 Toray Industries ARYLMETHYLENE UREE DERIVATIVE AND USE THEREOF
GB0525083D0 (en) 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
GB0525080D0 (en) 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
GB0525081D0 (en) 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
JP2009523161A (ja) 2006-01-11 2009-06-18 アストラゼネカ アクチボラグ モルホリノピリミジン誘導体と療法におけるその使用
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
EA200870217A1 (ru) 2006-01-30 2009-02-27 Экселиксис, Инк. 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции
WO2007105023A1 (en) 2006-03-15 2007-09-20 Csir Modulation of phosphoryl transferase activity of glutamine synthetase
JP5243696B2 (ja) 2006-03-17 2013-07-24 田辺三菱製薬株式会社 ベンゼン誘導体
US8044068B2 (en) 2006-04-04 2011-10-25 Taisho Pharmaceutical Co., Ltd Aminopyrrolidine compound
US20070293491A1 (en) 2006-04-19 2007-12-20 Novartis Vaccines And Diagnostics, Inc. Indazole compounds and methods for inhibition of cdc7
JP5225076B2 (ja) 2006-04-27 2013-07-03 田辺三菱製薬株式会社 チアゾール環を含むカルボン酸誘導体の医薬用途
GB0610909D0 (en) 2006-06-05 2006-07-12 Merck Sharp & Dohme Therapeutic treatment
US8222256B2 (en) 2006-07-05 2012-07-17 Exelixis, Inc. Methods of using IGFIR and ABL kinase modulators
CA2660758A1 (en) 2006-08-24 2008-02-27 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
JP2010501537A (ja) 2006-08-24 2010-01-21 アストラゼネカ アクチボラグ 増殖性障害の治療に有用なモルホリノピリミジン誘導体
WO2008125833A1 (en) 2007-04-12 2008-10-23 Piramed Limited Pharmaceutical compounds

Also Published As

Publication number Publication date
KR20090053928A (ko) 2009-05-28
CO6150160A2 (es) 2010-04-20
EP2057140A1 (en) 2009-05-13
HK1130776A1 (en) 2010-01-08
JP5534811B2 (ja) 2014-07-02
IL196998A0 (en) 2009-11-18
KR101435231B1 (ko) 2014-10-02
EP2057140B1 (en) 2012-08-08
NO20090631L (no) 2009-03-16
AU2007287428B2 (en) 2011-08-11
AR062526A1 (es) 2008-11-12
JP2010501534A (ja) 2010-01-21
CL2007002446A1 (es) 2008-04-04
UY30559A1 (es) 2008-03-31
MX2009002046A (es) 2009-03-06
US7750003B2 (en) 2010-07-06
CA2660758A1 (en) 2008-02-27
US20080171743A1 (en) 2008-07-17
WO2008023159A1 (en) 2008-02-28
AU2007287428A1 (en) 2008-02-28

Similar Documents

Publication Publication Date Title
PE20081362A1 (es) DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
PE20100138A1 (es) Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k
PE20090895A1 (es) Derivados de triazol como inhibidores de la jak quinasa
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20090773A1 (es) Derivados de morfolina pirimidina
NO20071593L (no) Pyrimidinderivater
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
PE20060479A1 (es) Compuestos heteroaril-aril-ureas como inhibidores de la quinasa
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
PA8632701A1 (es) Compuestos terapeuticos
PE20070517A1 (es) Derivados de imidazol como agentes inhibidores de la sintasa de aldosterona y aromatasa
AR066583A1 (es) Derivados de 3,3-espiroindolinona
DK1934174T3 (da) Azetidiner som MEK inhibitorer til behandling af proliferative sygdomme
AR054799A1 (es) Derivados de oxindol
SE0402735D0 (sv) Novel compounds
CR9459A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
PE20081393A1 (es) Derivados de quinolina como inhibidores de csf-1r
PE20090288A1 (es) Derivados de quinoxalina como inhibidores de la pi3 quinasa
PE20080948A1 (es) Derivados de imidazol como moduladores de la senda de hedgehog
AR072016A1 (es) Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato
AR066659A1 (es) Derivados de espiroindolinona
ATE476431T1 (de) Piperidin- und azetidinderivate als glyt1- inhibitoren

Legal Events

Date Code Title Description
FC Refusal